Department of Respiratory and Critical Care Medicine, Fujian Quanzhou First Hospital, Fujian Medical University, Quanzhou, China.
Pulmonary Medicine, The First Affiliated Hospital of Xiamen University, Xiamen, China.
J Clin Lab Anal. 2020 Aug;34(8):e23338. doi: 10.1002/jcla.23338. Epub 2020 Jul 14.
This study aimed to assess the circular RNA_0007385 (hsa_circ_0007385) expression in tumor/adjacent non-tumor tissues, and the correlation of its tumor expression with clinicopathological features as well as survival in non-small-cell lung cancer (NSCLC) patients.
210 NSCLC patients who underwent tumor resection were reviewed in this retrospective study. 210 tumor specimens and 81 paired adjacent specimens were collected, in which the hsa_circ_0007385 expression was detected by reverse transcription-quantitative polymerase chain reaction assay. Disease-free survival (DFS) and overall survival (OS) were recorded, and the last follow-up date was June 30, 2019.
Hsa_circ_0007385 was upregulated in tumor tissue compared with adjacent non-tumor tissue (P < .001), and ROC curve analysis revealed that hsa_circ_0007385 expression had an excellent value in distinguishing tumor tissue from adjacent non-tumor tissue with an area under curve of 0.922 (95% CI: 0.890-0.953). Tumor hsa_circ_0007385 high expression correlated with lymph node metastasis (P = .007) and higher TNM stage (P = .004). In addition, DFS (P = .028) and OS (P = .008) were both less favorable in patients with tumor hsa_circ_0007385 high expression compared to patients with tumor hsa_circ_0007385 low expression. Besides, the DFS (P = .008) and OS (P = .012) were also the worst in patients with tumor hsa_circ_0007385 high+++ expression, followed by patients with tumor hsa_circ_0007385 high++ expression and patients with tumor hsa_circ_0007385 high + expression, and the best in patients with tumor hsa_circ_0007385 low expression. Multivariate regression analysis elucidated that tumor hsa_circ_0007385 high expression independently predicted worse OS (P = .033).
Tumor hsa_circ_0007385 could be a novel biomarker for disease monitoring and prognosis prediction in NSCLC patients.
本研究旨在评估肿瘤/邻近非肿瘤组织中环状 RNA_0007385（hsa_circ_0007385）的表达，并分析其肿瘤表达与非小细胞肺癌（NSCLC）患者临床病理特征及生存的相关性。
本回顾性研究纳入了 210 例接受肿瘤切除术的 NSCLC 患者。共收集了 210 份肿瘤标本和 81 对邻近标本，通过逆转录定量聚合酶链反应检测 hsa_circ_0007385 的表达。记录无病生存期（DFS）和总生存期（OS），末次随访日期为 2019 年 6 月 30 日。
与邻近非肿瘤组织相比，肿瘤组织中 hsa_circ_0007385 表达上调（P<.001），ROC 曲线分析显示，hsa_circ_0007385 表达在区分肿瘤组织和邻近非肿瘤组织方面具有优异的价值，曲线下面积为 0.922（95%CI：0.890-0.953）。肿瘤 hsa_circ_0007385 高表达与淋巴结转移（P=.007）和更高的 TNM 分期（P=.004）相关。此外，与肿瘤 hsa_circ_0007385 低表达患者相比，肿瘤 hsa_circ_0007385 高表达患者的 DFS（P=.028）和 OS（P=.008）均较差。此外，肿瘤 hsa_circ_0007385 高+++表达患者的 DFS（P=.008）和 OS（P=.012）最差，肿瘤 hsa_circ_0007385 高++表达患者次之，肿瘤 hsa_circ_0007385 高+表达患者再次之，肿瘤 hsa_circ_0007385 低表达患者最好。多变量回归分析表明，肿瘤 hsa_circ_0007385 高表达独立预测 OS 较差（P=.033）。
肿瘤 hsa_circ_0007385 可能是非小细胞肺癌患者疾病监测和预后预测的新型生物标志物。
